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Preclinical studies suggested valproate increased brain γ -aminobutyric acid (GABA) with no major effects on brain glutamate
or glutamine. Valproate increased human cerebrospinal fluid GABA and glutamine in some studies; others reported no effect.
In vivo measurements of glutamate, glutamine, and GABA were made of a 14 cm3 volume in the occipital cortex using a 1H
spectroscopy with a 2.1 Tesla magnetic resonance spectrometer and an 8 cm surface coil. Ten control subjects and 14 patients with
refractory complex partial seizures were examined. Brain glutamine concentrations were above normal in three of five patients
taking valproate and two of nine taking carbamazepine or phenytoin. Mean glutamine levels of patients taking valproate were
higher than control subjects and patients taking carbamazepine or phenytoin. Brain glutamate concentrations were above normal
in four of nine patients taking phenytoin or carbamazepine and two of five taking valproate. Brain GABA levels were below
normal in four of nine patients taking carbamazepine or phenytoin and one of five taking valproate. Above normal glutamate or
below normal GABA was present in nine of 14 patients and may contribute to their refractory epilepsy. Increased brain glutamine
associated with valproate therapy may reflect mild hyperammonemia.
Key words: glutamine; glutamate; human; epilepsy; valproate; 1H nuclear magnetic resonance spectroscopy.Introduction
Carbamazepine, phenytoin, and valproate all treat com-
plex partial seizures effectively1, 2. Carbamazepine and
phenytoin are not thought to have a direct GABAer-
gic mechanism of action3, 4. These antiepileptic drugs
(AED) do not increase CSF or brain GABA signifi-
cantly in adult patients with epilepsy5–7.
The initial preclinical studies in rodents of the
neurochemical effects of valproate suggested a
GABAergic anticonvulsant mechanism8–11. Large
doses (400 mg/kg) of valproate increased rat whole
brain GABA by 46% without significant changes in
aspartate, glutamate, glutamine, or glycine8. Stud-
ies of epileptic children and adults treated with val-
proate reported increased GABA concentrations in
cerebrospinal fluid (CSF)12, 13. No significant alter-
ations in CSF GABA levels were seen in adult patients
with epilepsy, Parkinsonism, or schizophrenia treated
with valproate14–16.
The effect of valproate on glutamate and glutamine
concentrations appears dependent on the species and1059–1311/99/020120 + 08 $12.00/0dose studied9, 10, 17. Brain glutamate concentrations
were reported to be increased, decreased, and un-
changed in rodents treated with valproate9, 10, 17–19. In-
creased concentrations of glutamine were reported in
mouse brain, rat cortex, and baboon CSF17–20. Val-
proate was reported to increase CSF glutamine in chil-
dren but not in adults14, 21.
In vivo measurements of brain glutamate, glutamine,
and GABA in patients with epilepsy were made possi-
ble by advances in nuclear magnetic resonance (NMR)
spectroscopy22–25. We describe our initial experience
in making combined measurements of glutamate, glu-
tamine, and GABA in patients taking valproate, pheny-
toin, or carbamazepine.
Materials and Methods
Five men and five women volunteered as medica-
tion free, control subjects. The mean age of the non-
epileptic subjects was 36 years (SD 9, range 26–
58). Glutamine, glutamate, and GABA levels werec© 1999 British Epilepsy Association
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Fig. 1: A short-TE spectrum with and without the
‘metabolite-nulled’ inversion recovery sequence was
obtained in the same volume as for the GABA measurement
(top). Subtracting the short T1 weighted spectrum from the
unweighted spectrum yields a spectrum (bottom) containing
little or no signals originating from macromolecule
resonances. The remaining signals are all from small
molecules, metabolites, which have long T1 relaxation times.
The flat baseline, free of signals from macromolecules with
short T1 relaxation times, allows the metabolite signals to be
analyzed quantitatively. Abbreviations used:
N -acetylaspartate and other signals at 2.0 ppm (NAX),
creatine, phosphocreatine, and other signals at 3.0 ppm
(TCr), N -acetylaspartate (naa), glutamine (gln), glutamate
(glt), and lactate (lac).measured in 14 patients (9 women) with complex
partial seizures (Table 1). The mean age of the pa-
tients was 36 years (SD 8, range 25–53). Antiepilep-
tic drugs used included carbamazepine monotherapy
(4 patients), phenytoin monotherapy (4), phenytoin
with carbamazepine (1), valproate monotherapy (2),
and valproate with carbamazepine (3). All patients
were evaluated extensively by the Yale Epilepsy Pro-
gram and suffered from refractory complex partial
seizures. None showed an occipital focus on electroen-
cephalogram. Patients kept a seizure diary. Prior to each
spectroscopic measurement, patients were interviewed
concerning seizure frequency and side effects of the
medications. All subjects gave informed consent for
the study which was approved by the Yale Human In-
vestigations Committee.
Studies were performed at Yale Medical School with
a 2.1 Tesla (89.43 MHz for 1H) Oxford Magnet Tech-
nologies 1 meter bore magnet equipped with a modified
Biospec spectrometer (Bruker Instruments, Billerica,
MA, USA) and OMT shielded gradients and power
supplies (Oxford Magnetic Technology, Oxford, UK).
Each subject’s head was positioned in an adjustable
holder (designed for minimal motion and maximal
comfort) such that a flat surface spoiler and an 8 cm
distributed capacitance 1H transceiver radio-frequency
(RF) coil lay just below the occipital cortex. Prior to the
1H spectroscopy measurement a gradient echo image
of the subject’s brain was obtained. From the image,
a 3:0  1:5  3:0 cm (14 cm3) volume in the occipi-
tal cortex was chosen for spectroscopic measurements.
An automated shimming routine was used to optimize
the static .B0/ field homogeneity in the sensitive vol-
ume26.
Glutamine and glutamate measurements were made
using macromolecule suppressed, short echo time (TE)
spectra24, 27. Localization was achieved by a 3D-ISIS
sequence, outer volume suppression, selective excita-
tion, and a surface spoiler coil. An inversion recovery
pulse and a semiselective refocusing pulse were used
for water suppression. The TE time was 17 ms with the
semiselective refocusing pulse optimum at 2.30 ppm
and 7.16 ppm, repetition time of 4.1 s, and an inversion
recovery delay of 1.03 s. ‘Metabolite-nulled’ spectra
were obtained by a broadband inversion recovery se-
quence which suppresses all metabolites with a long
T1. Subtraction of the ‘metabolite-nulled’ (short T1
macromolecule resonances only) spectrum from the
full short-TE spectrum results in a flat spectral base-
line (Fig. 1). Other spectral acquisition conditions in-
cluded a sweep width of 2500 Hz and acquisition time
of 410 ms.
Glutamine and glutamate concentrations were mea-
sured as previously described22, 24. In vivo time do-
main data were zero filled to 32 768 points. Prior to
Fourier transformation, time domain spectra were fil-tered with a −2 Hz exponential function followed by
a 7.5 Hz Gaussian window. The processing added ap-
proximately 1 Hz to the natural linewidth. After Fourier
transformation, a zero-order phase correction was per-
formed. After subtraction of the metabolite nulled spec-
trum, a zero- and first-order baseline correction from
4.5 to −0:5 ppm and 10 to 5.5 ppm was performed.
Spectra were scaled by the amplitude of the creatine
resonance. The 1H spectral region between 1.6 and
3.1 ppm was deconvoluted using proprietary software
written in MATLAB. The coefficients for a system of
equations needed to estimate metabolite concentrations
were determined from localized spectra of model so-
lutions (phantoms) containing glutamate, glutamine,
GABA, creatine, aspartate, N -acetylaspartate, succi-
nate, and other brain metabolites22, 24. Using these in-
put functions, the in vivo spectrum was modeled as a
linear sum of these signals. A Gaussian function with
the same linewidth as creatine in the subject’s spec-
trum was used to apodize the spectra obtained from the
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Table 1:
ID Age yr Onset epilepsy yr Gender Frequency of Daily dose Blood levels
seizures in past month of antiepileptic drugs of drugs mg/l
a. 34 20 Female 30 Carbamazepine 1000 mg 11
b. 38 28 Female 30 Carbamazepine 1200 mg 6
c. 36 19 Male 0 Carbamazepine 1200 mg 9
d. 29 2 Female 30 Carbamazepine 500 mg 13
e. 52 18 Male 8 Carbamazepine 2000 mg 11
Phenytoin 500 mg 11
f. 29 23 Male 30 Phenytoin 700 mg 16
g. 38 32 Male 0 Phenytoin 400 mg 19
h. 53 6 Female 6 Phenytoin 300 mg 9
i. 39 14 Female 0 Phenytoin 300 mg 8
j. 34 5 Female 1 Carbamazepine 1200 mg 11
Valproate 1250 mg 51
k. 36 12 Female 2 Carbamazepine 1600 mg 9
Valproate 1500 mg 52
l. 25 12 Male 3 Carbamazepine 800 mg 10
Valproate 1500 mg 103
m. 25 16 Female 4 Valproate 3000 mg 78
n. 34 21 Female 15 Valproate 1500 mg 63pure compounds. This method is similar to that used by
Provencher28 except that the fit is in the frequency do-
main and macromolecules are suppressed by the pulse
sequence. The mean value of all control subjects was
assigned the concentrations of glutamine (4.2 mM),
glutamate (9.1 mM), and GABA (1.2 mM) for the oc-
cipital lobe measured using 13C spectroscopy and an
external concentration reference29.
Homonuclear editing of the 3.0 ppm C4 GABA res-
onance was performed using the spin–spin (J) edit-
ing pulse sequence described previously23, 24. The lo-
calization techniques were 3D-ISIS sequence, outer
volume suppression, selective excitation, and surface
spoiler coil. An inversion recovery pulse and a semis-
elective refocusing pulse was used for water suppres-
sion. Spectral editing was used to separate the GABA
C4 resonance at 3.0 ppm from overlapping resonances
by applying a 26.5 ms DANTE pulse applied symmetri-
cally in time about the center of the sequence to improve
editing selectivity to the 1.9 ppm C3 resonance. Spec-
tral acquisition conditions were TR 3.39 s, TE 68 ms,
sweep width 2500 Hz, and acquisition time 410 ms.
In the edited spectra, GABA was measured as pre-
viously described23, 25. In vivo time domain data were
zero filled to 32 768 points and apodized with a 3 Hz
exponential function prior to Fourier transformation.
The GABA resonance at 3.0 ppm in the 1H NMR edited
spectrum were integrated over a limited bandwidth and
compared with the limited bandwidth integrated reso-
nance of creatine obtained in the same measurement
set. Coefficients needed to convert the GABA/creatine
ratios to concentrations were measured in model solu-
tions23, 30.
Student’s t-test two-tailed probability distribution ta-
bles were used to calculate a 95% confidence interval
(95% CI) of the group mean difference. Tables based onthe binomial distribution were used to obtain the 95%
CI for population medians31. When multiple measure-
ments for an individual were available, the mean value
was used.
Results
There were no significant gender or age related dif-
ferences in brain glutamine levels of control subjects.
Brain glutamine concentrations were above normal in
three of five patients taking valproate (Fig. 2). Mean
glutamine levels of patients taking valproate (5.7 mM,
95% CI 4.4–6.9, n D 5) were higher than control sub-
jects (4.2 mM, 95% CI 4.0–4.4, n D 10, P < 0:01) and
patients taking carbamazepine or phenytoin (4.2 mM,
95% CI 3.9–4.6, n D 9, P < 0:01).
There were no significant gender or age related dif-
ferences in glutamate levels among control subjects.
Brain glutamate concentrations were above normal in
43% of patients including two patients taking valproate
(Fig. 3). Mean glutamate was higher in patients tak-
ing carbamazepine or phenytoin (9.9 mM, 95% CI
9.3–10.5, n D 9, P < 0:05) than in control subjects
(9.2 mM, 95% CI 9.0–9.5, n D 10). One patient taking
valproate had below normal glutamate.
There were no gender or age related differences
in occipital lobe GABA levels of our control sub-
jects. Brain GABA levels were below normal in 36%
of patients with epilepsy (Fig. 4). Mean GABA was
lower in patients taking carbamazepine or phenytoin
(1.0 mM, 95% CI 0.8–1.2, n D 9) than in control sub-
jects (1.2 mM, 95% CI 1.1–1.3, n D 10, P < 0:05).
There were no significant differences in mean or me-
dian GABA concentrations between patients treated
with valproate and carbamazepine or phenytoin.






















Fig. 2: Valproate increased human occipital lobe glutamine. Brain glutamine was above normal in 60% of patients taking valproate,
20% taking phenytoin, and 25% taking carbamazepine. The dashed lines indicate two standard deviations (2 SD) above and
below the mean of 10 normal subjects. Four patients on carbamazepine monotherapy, four on phenytoin monotherapy (to the right
in the phenytoin column) plus one on phenytoin and carbamazepine (to the left), and two patients on valproate monotherapy (to






















Fig. 3: Brain glutamate was above normal in 44% of patients taking carbamazepine or phenytoin and 40% of those taking
valproate or valproate and carbamazepine. The dashed lines indicate two standard deviations (2 SD) above and below the
mean of 10 normal subjects.


















Fig. 4: Human occipital lobe GABA concentrations are decreased in 36% of patients with complex partial seizures. Brain GABA
was below normal in 50% of patients taking carbamazepine, 40% taking phenytoin, and 20% taking valproate. The dashed lines



























Fig. 5: Schematic of glutamate–glutamine cycling between neurons and glia. Neuronal glutamate is lost during glutamate
transmitter release. In glutamatergic neurons, the continuing loss of glutamate would deplete mitochondria of critical TCA cycle
intermediates and lead to neuronal energy failure, possible mitochondrial damage, and potential neuronal apoptosis52–54. The
metabolic pathway through phosphate activated glutaminase (PAG), primarily localized in neurons, supplies the needed carbon to
maintain the TCA cycle intermediates37, 52, 55. The flow through PAG is proportional to neuron–glia cycling and controls neuronal
glutamate concentrations50, 52, 55. The action of glutamate in the synaptic cleft is terminated by glial uptake mechanisms.
Glutamine synthetase (GS), exclusively found in glia, is critical in recycling the carbon skeletons lost from neurons through
neurotransmitter release. The rate of glutamine synthesis is proportional to the rate of ammonia (NH3) detoxification and
neuron–glia cycling37, 52. Aspartate aminotransferase and glutamate dehydrogenase (GDH) catalyze the rapid equilibrium
between glutamate and -ketoglutarate. GDH is enriched in glia. The glycolytic and pyruvate dehydrogenase (PDH) pathways
from glucose feed substrate into the tricarboxylic acid (TCA) cycle providing energy. However, this metabolic pathway cannot
replenish TCA cycle intermediates (anaplerosis). The anaplerotic pathway from glucose through pyruvate carboxylase (PC) to
glutamate is active in glia exclusively and replenishes TCA cycle intermediates lost when glutamine is exported to neurons and
blood.
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the spectroscopy was eight (95% CI 0.3–30, n D 9) for
the group taking carbamazepine or phenytoin and three
(range 1–15, n D 5) for the group taking valproate.
Patients taking carbamazepine or phenytoin had the
best and the worst seizure control. Three of four pa-
tients with daily seizures had below normal GABA.
Mean GABA was lower in patients with daily seizures
(0.8 mM, 95% CI 0.7–1.1, n D 4) than patients with
fewer than one seizure a month (1.2 mM, 95% CI 0.8–
1.5, n D 3, P < 0:05). Two of four patients with daily
seizures had above normal brain glutamate. However,
mean glutamate was not significantly higher with daily
seizures (10.3 mM, 95% CI 9.0–11.6, n D 4) than
with better control (9.7 mM, 95% CI 8.9–10.4, n D 3).
Mean brain glutamine was the same for both groups
(daily seizures 4.5 mM, 95% CI 4.1–4.9, n D 4; best
control 4.2, 95% CI 2.9–5.5, n D 3).
Discussion
Valproate did not increase significantly GABA con-
centrations in the occipital lobe of adult patients with
complex partial seizures. There was no difference in
brain GABA between patients taking carbamazepine or
phenytoin and patients taking valproate. Brain GABA
in many animal models increases at higher doses of
valproate9, 10, 17. The median daily dose taken by our
patients (22 mg/kg, range 18–33, n D 5) was low
compared to the doses used in animal models. Of the
newer AEDs, gabapentin, topiramate, and vigabatrin
clearly increase brain GABA in epilepsy patients with
doses used clinically25, 32–35. Topiramate, gabapentin,
and lamotrigine increase brain GABA in healthy sub-
jects36. Curiously, only vigabatrin significantly raises
brain GABA in rodent models.
Valproate increased brain glutamine in 60% of pa-
tients. The rate of glutamine synthesis is limited pri-
marily by its substrates, glutamate and ammonia37–39.
Raised ammonia levels increase glutamine synthesis
and decrease catabolism, thereby raising glutamine
concentrations. Hyperammonemia is a common con-
sequence of valproate administration40. Valproate in-
creases production of ammonia in human kidney and
increases glutamine removal41. Valproate also inhibits
the activity of the urea cycle and can unmask partial de-
fects in various enzymes42, 43. Whether our patients had
asymptomatic defects in urea cycle enzymes unmasked
by valproate or merely asymptomatic mild hyperam-
monemia is unknown. None had clinical signs of hep-
atic or renal disease and had normal findings on routine
blood work. Blood ammonia was not tested. Elevated
CSF glutamine was reported in children treated with
valproate or barbiturates and adults treated with phe-
nobarbital6, 21, 44. Adult patients treated with vigabatrinalso had above normal brain glutamine24. Whether the
metabolic changes associated with increased glutamine
contribute to improved seizure control or deleterious
side-effects remains to be investigated.
Glutamate concentrations are higher in epileptic hu-
man cortex45–47. A third of our patients had above nor-
mal glutamate in cortex remote from the seizure focus.
Two thirds, nine of 14, had either above normal gluta-
mate or below normal GABA. Low brain GABA levels
are associated with frequent seizures7. Either condi-
tion could contribute to increased cerebral excitabil-
ity3, 4, 35, 48.
Elevated serum ammonia may have an impact on
seizure control through its effects on cerebral glu-
tamate homeostasis. Brain glutamate concentrations
are influenced primarily by glutamate concentrations
within glutamatergic neurons49, 50. Significant changes
in the glial glutamate concentrations would be difficult
to detect. Glutamate levels in astrocytes (<1 mM) are
far lower than those found in glutamatergic neurons. It
is within the range of the Michaelis–Menten constant
of glutamine synthetase which would allow the rate
of glutamine synthesis to respond to an increase in
glial glutamate concentration37–39. Glia efficiently re-
move glutamate released by neurons and terminate the
action of released glutamate (Fig. 5). Inhibition of glu-
tamine synthesis produces seizures by raising both
glial and extracellular glutamate concentrations45.
Increased blood ammonia is thought to lower glial
glutamate concentrations significantly while raising
glutamine concentrations38, 39, 51. Decreased glial glu-
tamate would facilitate glutamate uptake, potentially
making the brain less excitable.
Conclusions
Valproate does not increase significantly brain GABA
in patients with epilepsy. Increased glutamine may re-
flect mild hyperammonemia associated with valproate
therapy. Below normal GABA or above normal glu-
tamate was present in 64% of patients with refractory
complex partial seizures and may contribute to poor
seizure control.
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